ARID1A and cancer: Associated with lineage-specific enhancer activation [22,24]. Compensates for ARID1A loss in some cancers and is synthetic lethal with ARID1A loss [24,143]. Dual loss of ARID1A/ARID1B can also be pro-tumorigenic [144].